"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Descriptor ID |
D004357
|
MeSH Number(s) |
G07.690.773.968.477
|
Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2002 | 0 | 5 | 5 |
2003 | 0 | 10 | 10 |
2004 | 1 | 8 | 9 |
2005 | 1 | 12 | 13 |
2006 | 0 | 4 | 4 |
2007 | 1 | 7 | 8 |
2008 | 0 | 8 | 8 |
2009 | 0 | 7 | 7 |
2010 | 0 | 7 | 7 |
2011 | 0 | 1 | 1 |
2012 | 0 | 2 | 2 |
2013 | 0 | 7 | 7 |
2014 | 0 | 6 | 6 |
2015 | 0 | 4 | 4 |
2016 | 0 | 4 | 4 |
2017 | 0 | 4 | 4 |
2019 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Dos Santos DZ, Elbaz M, Branchard E, Schormann W, Brown CE, Meek AR, Njar VCO, Hamilton RJ, Reed MA, Andrews DW, Penn LZ. Sterol-like drugs potentiate statin-triggered prostate cancer cell death by inhibiting SREBP2 nuclear translocation. Biomed Pharmacother. 2024 Aug; 177:116934.
-
Nayak AP, Lim JM, Arbel E, Wang R, Villalba DR, Nguyen TL, Schaible N, Krishnan R, Tang DD, Penn RB. Cooperativity between ß-agonists and c-Abl inhibitors in regulating airway smooth muscle relaxation. FASEB J. 2021 07; 35(7):e21674.
-
Meister KS, Godse NR, Khan NI, Hedberg ML, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR, Duvvuri U. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. Sci Rep. 2019 06 24; 9(1):9130.
-
Katragkou A, McCarthy M, Meletiadis J, Hussain K, Moradi PW, Strauss GE, Myint KL, Zaw MH, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ, Petraitis V. In vitro combination therapy with isavuconazole against Candida spp. Med Mycol. 2017 Nov 01; 55(8):859-868.
-
Marchesi I, Sanna L, Fais M, Fiorentino FP, Giordano A, Bagella L. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. J Cell Physiol. 2018 Mar; 233(3):2360-2365.
-
Liu G, Xue X, Gao C, Huang J, Qi D, Zhang Y, Dong JZ, Ma CS, Yan GX. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation. J Am Heart Assoc. 2017 May 18; 6(5).
-
Gopalakrishnapillai A, Kolb EA, McCahan SM, Barwe SP. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leuk Res. 2017 07; 58:91-97.
-
Karmaker A, Costanzo CM, Schwartz MZ. Is OM-3 synergistic with GLP-2 in intestinal failure? J Surg Res. 2017 01; 207:7-12.
-
Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget. 2016 Jul 26; 7(30):48280-48295.
-
Tao Y, Zhang X, Markovic-Plese S. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). J Neuroimmunol. 2016 09 15; 298:181-8.